


Spatial multi-omics collaboration helps publish


Nature Genetics
(IF: 30.8)

- Transcriptome
- Spatial transcriptome
- Single-cell transcriptome

A New Start

Spatial multi-omics reveals new subtypes and new diagnosis and treatment systems for clear cell renal cell carcinoma



nature genetics 

Article <https://doi.org/10.1038/s41588-024-01662-5>

Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression



Scan to read the full text

Received: 20 February 2023 Junyi Hu¹*, Shao-Gang Wang¹*, Yixin Hou¹*, Zhaohui Chen^{2,3,4}, Lilong Liu¹,
Ruizhi Li⁵, Nisha Li⁶, Lijie Zhou⁷, Yu Yang⁸, Liping Wang⁹, Liang Wang⁹,
Xiong Yang⁹, Yichen Lei⁹, Changqi Deng⁹, Yang Li¹⁰, Zhiyao Deng¹¹,
Yuhong Ding¹², Yingchun Kuang¹³, Zhipeng Yao¹⁴, Yang Xun¹⁵, Fan Li¹⁶, Heng Li¹⁷,
Jia Hu¹⁸, Zheng Liu¹⁹, Tao Wang²⁰, Yi Hao²¹, Xuanmao Jiao²², Wei Guan²³,
Zhen Tao^{24,25}, Shancheng Ren^{26,27} & Ke Chen^{28,29}

Check for updates

Article Highlights

- The first large cohort study of clear cell renal cell carcinoma (ccRCC) integrating conventional multi-omics and spatial multi-omics;
- A new subtype of ccRCC, dedifferentiated clear cell subtype ccRCC(DC-CD-ccRCC) was proposed, which has unique immune, metabolic and clinical characteristics;
- A new molecular classification and treatment system for ccRCC was established, which provides high guidance value for the diagnosis, surgery and drug administration of renal cancer and even personalized precision medicine.

In-depth Cooperation

OEBiotech (Omicsempower's parent company) is one of the author's signed units treatment systems for clear cell renal cell carcinoma

¹Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ²Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ³Shanghai Luming Biotech, Shanghai, China. ⁴Shanghai OE Biotech, Shanghai, China. ⁵Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ⁶Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. ⁷Department of Pathology, Baylor Scott & White Medical Center, Temple, TX, USA. ⁸Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. ⁹Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ¹⁰Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Philadelphia, PA, USA. ¹¹Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. ¹²Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ¹³Department of Urology, Second Affiliated Hospital of Naval Medical University, Shanghai, China. ¹⁴These authors contributed equally: Junyi Hu, Shao-Gang Wang, Yixin Hou, Zhaohui Chen. ✉e-mail: deniskwan@gmail.com; ztao@tmu.edu.cn; renshancheng@gmail.com; shenke@hust.edu.cn

Contact us



Singapore :
112 ROBINSON ROAD #03-01



Email :
eva.zhang@omicsempower.com

Germany :

Kreuzstr.60,40210 Düsseldorf



More information is welcome to visit
www.omicsempower.com